Latest1 information on COVID-19
©2022 Stanford Medicine
Transplantation for Patients With Chronic Lymphocytic Leukemia
Not Recruiting
Trial ID: NCT00186303
Purpose
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell
transplantation for the treatment of chronic lymphocytic leukemia.
Official Title
Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia
Stanford Investigator(s)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Wen-Kai Weng, MD, PhD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)
Eligibility
Inclusion Criteria:- adequate organ function
- normal bone marrow cytogenetics Exclusion Criteria:- active CNS disease
- For autologous patients more than 30% bone marrow involvement
Intervention(s):
procedure: high dose chemotherapy then autologous hematopoietic cell transplant
procedure: ablative allogeneic hematopoietic cell transplant
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822